Would you like to contribute to this site?
Arthritis Menu
Submit an Article
Submit a Tip
Place your Ad
Add URL
Arthritis Questions?
Contact Us
Related Topics:
Anklosing Spondylitis
Ankylosing Spondalitis
Ankylosing Spondilitis
Ankylosing Spondylitis
Ankylosing Spondylitis Arthritis
Ankylosing Spondylitis Cure
Ankylosing Spondylitis Diagnosis
Ankylosing Spondylitis Diet
Ankylosing Spondylitis Disease
Ankylosing Spondylitis Exercises
Ankylosing Spondylitis Medication
Ankylosing Spondylitis Research
Ankylosing Spondylitis Symptoms
Ankylosing Spondylitis Treatment
Juvenile Ankylosing Spondylitis
Remicade Ankylosing Spondylitis
What Is Ankylosing Spondylitis
Other Channels:
|
 |
|
|
|
|
|
|
|
|
Recent Questions and Answers
|
|
|
|
|
|
|
|
Recent Ankylosing Spondylitis Diet News:
|
|
|
Pfizer (NYSE: PFE) today announced new results from multiple studies of ENBREL (etanercept), further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists worldwide. Eighteen abstracts across four indications, including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe ...
MSD (known as Merck in the United States and Canada) today announced that the European Commission (EC) ...
NEW GARDEN — Today will be a special day for Paul McGuire. It marks the 10th straight Father's Day in which he will be able to shoot hoops with his son.
Research and Markets has announced the addition of Decision Resources, Inc.'s new report "Ankylosing Spondylitis: Surveyed Rheumatologists Await Non-TNF-Alpha Inhibitor Therapies in an Underserved Market" to their offering.
Amgen and Pfizer Inc. today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States .
| |
| |
|
|
|
Additional Ankylosing Spondylitis Diet Resources:
|
|
|
|
|
|
|
|
|
Want your site featured on this page?
|
|
 |
|